Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Response-Guided Sequential Mepolizumab and Stapokibart in CRSwNP with Severe Eosinophilic Asthma
ChiCTR2600127395Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of mepolizumab and stapokibart in chronic rhinosinusitis with nasal polyps (CRSwNP) and eosinophilic asthma (EA) (5 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Nasosinusitis Response Rate at Week 12. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
mepolizumabstapokibart
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)eosinophilic asthma (EA)
Beyond the preview
Go deeper on ChiCTR2600127395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127395.